American College Of Surgeons - Inspiring Quality: Highest Standards, Better Outcomes

Return to Screening PDSA and Clinical Study: Update on COVID-19 Disruptions

We are aware of the surges in COVID-19 cases that are occurring across the United States and realize some hospitals are having to reallocate their intensive care beds, hospital beds, and staff resources. While we do hope that cancer care and cancer screening can remain a priority, we realize there may be temporary challenges with full participation in the Return to Screening Plan/Do/Study/Act (PDSA) and Clinical Study.

What should we do if our program is being overwhelmed by the surge in COVID cases?

Each accredited program has to manage local cancer resources and screening efforts to the best of its ability. If you are experiencing delays due to a local COVID-19 surge, we would expect that you would document in the cancer committee minutes reasons behind curtailing screening and the specific circumstances involved. Please continue to record the number of screenings performed each month until November 31. Use REDCap for the study or the online writeable forms.

Other Frequently Asked Questions

What are we supposed to do with form B/C each month?

You are required to complete forms B and C each month, in particular noting any interventions implemented and the number of screenings performed for that month.

Of note, only those programs that are participating in the clinical study that submitted REDCap form A will have received form B/C. If you are only participating in the PDSA, you will use the writeable forms available online and include them in your PRQ.

If you are participating in the clinical study and did not receive form B/C, first check your spam/junk folder for an e-mail from The subject line is "Form B/C: Post-Intervention Monthly Data Collection and Intervention Log," and the disease site will also be included in the subject line. While regular reminders with access to your form B/C are sent through REDCap, we recommend bookmarking the URL of form B/C to easily access it each month. If you cannot locate form B/C or need to update your contact information, please e-mail Jessica Dangles ( and include the name and e-mail of the individual who submitted the form as well as the disease site(s). The REDCap form B/C can be opened and edited at any time before the final submission.

What return to screening interventions are we supposed to implement each month?

First of all, it is important that you actively monitor the number of screenings that are being performed each month from June through the end of November. If the intervention(s) you initiated is(are) working well and your monthly screening volumes continue to achieve or exceed your monthly target, then you may not need to initiate any other interventions. If the volumes drop below your target, it is best to either re-activate the first intervention or initiate another intervention. Please continue to record your post-intervention monthly screening rates through REDCap if you are participating in the clinical study or through the online forms if you are only participating in the PDSA.

What if I submitted incorrect information on form A via REDCap or need to change the point of contact?

Please e-mail Jessica Dangles, ( and include the name and e-mail of the individual who submitted the form as well as the disease site(s).

Additional information, webinar recordings, and FAQs for the Return to Screening PDSA Clinical Study are available online.

Brief Review: The Role of Genomics in the Care of Surgical Patients with Cancer

In a recent issue of the American College of Surgeons Bulletin Brief, we presented the first entry in a new series of current literature reviews called Brief Reviews. This entry is part one of a two-part concise review of current literature relevant to the use of genomic testing to optimize care for surgical patients with cancer. Part one was authored by Angela Lee, MD, and Ryan Fields, MD, FACS, department of surgery, Washington University, St. Louis, MO.

Read the full text of this first entry in the series, "The Role of Genomics in the Care of Surgical Patients with Cancer ."

Three Breast Cancer Sessions at Clinical Congress 2021

Clinical Congress will be virtual this year! If you are looking for information on breast cancer, Clinical Congress offers at least three sessions specifically focused on the topic.

Panel session PS364, Improving Breast Cancer Outcomes in Black Women: Time for a Change, will be held on Monday, October 25 at 2:00 pm CT. African-American women have the highest mortality rate of all women with breast cancer. A significant number of African-American women present at an earlier age of diagnosis as well as with more advanced stage of disease. In 2018, the American College of Radiology and the Society of Breast Imaging reclassified recommendations for screening this population based on disease prevalence, mortality, early age onset, and genetic predisposition. High-risk screening and risk reduction strategies are imperative in the prevention and treatment of this high-risk population. This panel will discuss barriers in access to screening and treatment; current recommendations for screening, including risk-assessment models, modalities, and frequencies recommended for African-American women; and the impact of and strategies to reduce delays in diagnosis and treatment in this population.

This session will be moderated by the Commission on Cancer (CoC) Oncology Lecturer, Lisa A. Newman, MD, MPH, FACS, from New York, NY. Anita T. Johnson, MD, FACS, from Canton, GA, will co-moderate.

On Tuesday, October 26 at 12:00 noon CT, you can Meet the Experts during ME443 to learn more about Breast Cancer Management 2021. This session will be moderated by Lee G. Wilke, MD, FACS, from Madison, WI.

On Wednesday, October 27, panel session PS512, Oncoplastic Breast Surgery: The Why and How, will take place at 9:00 am CT. This session will be moderated by Ronda S. Henry-Tillman, MD, FACS, of Little Rock, AR, and co-moderated by Kathie-Ann P. Joseph, MD, FACS, of New York, NY. If you attended the American College of Surgeons (ACS) Quality and Safety Conference VIRTUAL in July, you may have seen Dr. Joseph speak on the panel session Re-Engagement in Cancer Screening in the Era of COVID-19: How to Bring our Patients Back.

To learn more about all the cancer programming at this year's Clinical Congress, please visit our web page. Be sure to check future editions of this newsletter for updates.